Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2006/086561NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS
WO 17.08.2006
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2006/004599 Applicant NEW YORK BLOOD CENTER Inventor JIANG, Shibo
The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
2.WO/2021/206638VACCINE AND/OR ANTIBODY FOR VIRAL INFECTION
WO 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/SG2021/050197 Applicant INTRA-IMMUSG PRIVATE LIMITED Inventor ZENG, Qi
The present invention relates to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N-protein and/or an immunogenic fragment thereof and uses thereof. The invention also includes a nucleic acid molecule encoding the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof; and uses thereof. The SARS-CoV-2 N protein and/or immunogenic fragment thereof may be produced by recombinant DNA technology or may be chemically synthesised. In particular, the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof and/or nucleic acid molecule encoding the SARS-CoV-2 N-protein and immunogenic may be for use as a vaccine. The invention further includes an antibody capable of binding to the SARS-CoV-2 N-protein or antigen-binding fragment thereof and uses thereof.
3.20210353620METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS
US 18.11.2021
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No 17320069 Applicant The University of Vermont and State Agricultural College Inventor Vikas Anathy

Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

4.WO/2021/228092NOVEL MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF
WO 18.11.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/093083 Applicant CHANG GUNG MEMORIAL HOSPITAL, LINKOU Inventor HUANG, Kuan-Ying
Provided are novel monoclonal antibodies or the antigen-binding fragments thereof, which bind to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or angiotensin-converting enzyme 2 (ACE2). Also provided are a pharmaceutical composition and a kit for detecting the presence of SARS-CoV-2 in a sample comprising the novel monoclonal antibody or the antigen-binding fragments thereof. Also disclosed herein are methods for detection or prevention and/or treatment of SARS-CoV-2 or a disease mediated by a disease mediated by ACE2.
5.WO/2021/216584USE OF SURFACTANT PROTEIN D TO TREAT VIRAL INFECTIONS
WO 28.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/028207 Applicant AIRWAY THERAPEUTICS, INC. Inventor KINGMA, Paul
Some embodiments of the methods and compositions provided herein relate to the use of surfactant protein D (SP-D) to treat or ameliorate a viral infection in a subject. In some embodiments, the viral infection comprises a coronavirus, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some embodiments include the use of certain formulations comprising a recombinant human SP-D (rhSP-D).
6.WO/2021/257607TREATMENT FOR HUMAN CORONAVIRUS INFECTION
WO 23.12.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/037486 Applicant THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND Inventor BIX, Gregory Jaye
Treating a human coronavirus (hCoV) infection includes administering an effective amount of an inhibitor of an α5- or αv-containing integrin to a subject in need thereof. The integrin inhibitor can be ATN-161. The hCoV can be SARS-CoV or SARS-CoV-2.
7.WO/2021/248279ANTIBODIES AGAINST SARS-COV-2 S1 SPIKE PROTEIN
WO 16.12.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2020/094953 Applicant ACTIVE MOTIF SHANGHAI LIMITED Inventor LU, Yanan
Provided are recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein, and methods of use. In various embodiments, the antibodies are fully human antibodies that bind to SARS-CoV-2 spike protein. In some embodiments, the antibodies are useful for inhibiting or neutralizing SARS-CoV-2 activity, thus providing a means of treating or preventing COVID-19 infection in humans. In some embodiments, provided is a combination of one or more antibodies that bind to the SARS-CoV-2 spike protein for use in treating COVID-19 infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the SARS-CoV-2 spike protein. In certain embodiments, the antibodies can be used to make an in vitro diagnostic for detection of COVID-19 in human and non-human animal samples. In still other embodiments, the antibodies can be used to remove virus from patient plasma via plasmapheresis.
8.WO/2022/003530NEUTRALIZING ANTIBODIES TO SARS CORONAVIRUS-2
WO 06.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/IB2021/055755 Applicant FONDAZIONE TOSCANA LIFE SCIENCES Inventor ANDREANO, Emanuele
The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against SARS-CoV-2. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 dependent diseases.
9.WO/2021/206636ANTIGEN-BINDING PROTEIN TO SARS-CoV-2
WO 14.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/SG2021/050195 Applicant AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH Inventor WANG, Cheng-I
The present invention relates to provide antigen-binding proteins that are capable of binding to and/or neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In one embodiment, the antigen-binding proteins are capable of binding to a spike protein of SARS-CoV-2 including receptor-binding domain (RBD) of SARS-CoV-2. The present invention also provides products comprising the same and methods of using the same for the treatment of SARS-CoV-2 infection or for detecting the presence of SARS-CoV-2 in a sample.
10.WO/2007/084583SOLUBLE FRAGMENTS OF THE SARS-COV SPIKE GLYCOPROTEIN
WO 26.07.2007
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2007/001270 Applicant GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Inventor DIMITROV, Dimiter, S.
The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins that include the spike protein or a portion thereof; peptidomimetics; vaccines; methods for vaccination and treatment of severe acute respiratory syndrome; antibodies; aptamers; and kits containing immunological compositions, or antibodies (or aptamers) that bind to the spike protein.